EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische Studie

Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study

Lucía Pérez-Lamas, Raquel de Paz Arias, Rosa Mª Ayala Díaz, Luis Felipe Casado Montero, Ángel Ramírez Payer, Magdalena Sierra, Francisca Ferrer Marín, Raúl Pérez López, Blanca Xicoy Cirici, Juan Luis Steegmann, María Teresa Gómez Casares, Joaquín Martínez-López und 1 weitere

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05662-7 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Annals of Hematology, 2024. Verfasst von Lucía Pérez-Lamas und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Doctor José Molina Orosa, Lanzarote, Spain. Hauptthemen laut MEDLINE: Nitriles, Aniline Compounds, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the field of chronic myeloid leukemia (CML), new strategies are needed to increase the rate of successful treatment discontinuations, a crucial goal in this disease. Anti-PD-L1 checkpoint inhibitors are a promising therapeutic approach in CML after the demonstration of an increase of these inhibitory molecules in patients with CML. A phase Ib/II (NCT04793399, registration date March 11, 2021) open-label exploratory trial has been conducted to evaluate the safety of atezolizumab, a humanized anti-PD-L1 antibody, in combination with bosutinib in patients with newly diagnosed chronic phase CML. A total of 36 patients were planned to be enrolled, but the study had to be prematurely terminated due to safety concerns. Nine patients were included in the study, and only 8 went on to receive the combination with atezolizumab. There were a total of 44 adverse events (AEs) during the study period. The most frequent were gastrointestinal (50%), mostly mild (86% grade 1-2). The most serious AEs were hepatic. There were 17 hepatic AEs in 5 patients. Of the hepatic AEs 5 were during the bosutinib monotherapy phase and 12 during the combination phase (AST increase x4, ALT increase x4, blood bilirubin increase x1, alkaline phosphatase elevation x2, GGT increase x2), most of them grade 3-4. There were 2 patients who presented a dose-limiting toxicity; a grade 3 elevation of transaminases, that led to premature termination of the study. The combination of atezolizumab with bosutinib presents hepatotoxicity as a dose-limiting effect and therefore we do not recommend to explore this combination in future studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NitrilesAniline CompoundsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsChemical and Drug Induced Liver InjuryQuinolinesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansMaleFemaleMiddle AgedAgedAdultDose-Response Relationship, Drug

Stichwörter der Autor:innen

AtezolizumabBosutinibCheckpoints inhibitorsChronic myeloid leukemiaHepatotoxicityPD-1PD-L1

Substanzen

bosutinibNitrilesAniline CompoundsAntibodies, Monoclonal, HumanizedQuinolinesatezolizumab

Autor:innen und Institutionen

  • Hospital Universitario Doctor José Molina Orosa, Lanzarote, Spain.
  • Hospital Universitario La Paz, Madrid, Spain.
  • Hospital Universitario Doce de Octubre, Madrid, Spain.
  • Hospital Virgen de la Salud, Toledo, Spain.
  • Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Hospital Universitario de Salamanca, Salamanca, Spain.

Zitieren

APA

Pérez-Lamas, L., de Paz Arias, R., Díaz, R. M. A., Montero, L. F. C., Payer, Á. R., Sierra, M., Marín, F. F., López, R. P., Cirici, B. X., Steegmann, J. L., Gómez Casares, M. T., Martínez-López, J., & García-Gutiérrez, V. (2024). Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study. Annals of Hematology. https://doi.org/10.1007/s00277-024-05662-7

Vancouver

Pérez-Lamas L, de Paz Arias R, Díaz RMA, Montero LFC, Payer ÁR, Sierra M, et al. Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study. Annals of Hematology. 2024. doi:10.1007/s00277-024-05662-7

BibTeX
@article{PrezLamas2024,
  author = {Pérez-Lamas, Lucía and de Paz Arias, Raquel and Díaz, Rosa Mª Ayala and Montero, Luis Felipe Casado and Payer, Ángel Ramírez and Sierra, Magdalena and Marín, Francisca Ferrer and López, Raúl Pérez and Cirici, Blanca Xicoy and Steegmann, Juan Luis and Gómez Casares, María Teresa and Martínez-López, Joaquín and García-Gutiérrez, Valentín},
  title = {Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05662-7}
}
Kostenlos starten →